#1 Clinical Trials Search in Europe

Mexiletine Hydrochloride

This article discusses a clinical trial investigating the use of Mexiletine Hydrochloride, alongside Amitriptyline, for treating painful neuropathy in HIV-infected patients. The study aims to assess the efficacy, safety, and tolerability of these medications in reducing pain intensity associated with HIV-related peripheral neuropathy. This research is significant as it represents one of the first large-scale controlled clinical trials for symptomatic therapy of this condition.

Table of Contents

What is Mexiletine Hydrochloride?

Mexiletine Hydrochloride is a medication that has shown promise in managing painful neuropathies, particularly in patients with HIV infections[1]. Neuropathy is a condition that affects the nerves, often causing pain, numbness, or weakness in various parts of the body. In the context of HIV infections, neuropathy can be a challenging and painful complication for many patients.

Medical Conditions Treated

According to the clinical trial data, Mexiletine Hydrochloride is being studied for its effectiveness in treating:

  • HIV-related painful peripheral neuropathy: This is a type of nerve damage that occurs in some people with HIV, causing pain, burning sensations, or numbness, typically in the hands and feet[1].
  • Peripheral Nervous System Disease: This broader category includes various conditions affecting the nerves outside the brain and spinal cord[1].

Clinical Trial Overview

A Phase II/III double-blind study was conducted to assess the efficacy, safety, and tolerability of Mexiletine Hydrochloride in reducing pain intensity for patients with HIV-related painful peripheral neuropathy[1]. This trial is significant because it represents one of the first large-scale controlled clinical trials for symptomatic therapy of painful HIV-related neuropathy.

Comparison with Other Medications

In the clinical trial, Mexiletine Hydrochloride was compared with two other medications:

  1. Amitriptyline Hydrochloride: Another medication used for managing painful neuropathies[1].
  2. Benztropine Mesylate: Used as an active placebo in the study to mimic the side effects of the other drugs[1].

The inclusion of Benztropine Mesylate as an active placebo is an interesting aspect of this study. An active placebo is a substance that produces similar side effects to the drugs being tested but doesn’t have the same therapeutic effect. This helps to maintain the “blind” nature of the study, as participants are less likely to guess which treatment they’re receiving based on side effects.

Dosage and Administration

The clinical trial provides some insights into how Mexiletine Hydrochloride might be administered:

  • Doses were gradually increased over 4 weeks until a minimum effective dose or maximum tolerated dose (MTD) was reached[1].
  • After reaching the effective or maximum dose, patients were treated for at least 4 additional weeks[1].
  • If no pain relief was observed after 14 days, the dose could be doubled or increased to the maximum allowable dose[1].
  • If no improvement occurred within 14 days after the dose increase, patients had the option to discontinue the medication[1].

Potential Side Effects

While the clinical trial data doesn’t provide specific information about side effects of Mexiletine Hydrochloride, it’s mentioned that both Mexiletine and Amitriptyline are associated with certain toxicities[1]. The use of Benztropine Mesylate as an active placebo to mimic mild side effects suggests that patients might experience some mild adverse effects while taking Mexiletine Hydrochloride. However, it’s important to note that the specific nature and severity of these side effects are not detailed in the provided information.

Aspect Details
Study Type Phase II/III Double-Blind Study
Main Drugs Studied Mexiletine Hydrochloride, Amitriptyline Hydrochloride
Condition HIV-related painful peripheral neuropathy
Primary Objective Assess efficacy, safety, and tolerability in reducing pain intensity
Study Design Randomized, gradual dose increase, 8-week treatment period
Placebo Benztropine Mesylate (active placebo)
Measurements Neurologic exams, twice-daily pain intensity ratings
Follow-up Weeks 2, 4, 8, and 10 days post-treatment

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to assess how well Mexiletine Hydrochloride and Amitriptyline work in reducing pain intensity for patients with HIV-related painful peripheral neuropathy. The study also aims to evaluate the safety and tolerability of these medications.
  • What is Mexiletine Hydrochloride? Mexiletine Hydrochloride is a medication being studied in this trial for its potential to manage painful neuropathies, particularly those related to HIV infection. It's being compared to Amitriptyline, another drug used for similar purposes.
  • How is the study conducted? Patients are randomly assigned to receive either Mexiletine, Amitriptyline, or Benztropine (which acts as an active placebo). The doses are gradually increased over 4 weeks until an effective dose is reached. Patients then continue treatment for at least 4 more weeks before tapering off.
  • What measurements are taken during the study? The study includes neurologic exams at the beginning and end of treatment. Patients are also asked to rate their pain intensity twice daily. Follow-up visits occur at weeks 2, 4, and 8, with a final check-up 10 days after completely stopping the medication.
  • What happens if the treatment isn't working? If a patient experiences no pain relief after 14 days of treatment, their dose may be doubled or increased to the maximum allowable dose. If there's still no improvement within 14 days after this increase, patients have the option to stop taking the study medication.

Ongoing Clinical Trials on Mexiletine Hydrochloride

  • Study Comparing the Safety and Effectiveness of Mexiletine PR and Mexiletine IR for Adults with Non-Dystrophic Myotonias

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy

  • Long-Term Safety and Efficacy Study of Mexiletine Hydrochloride for Patients with Myotonic Dystrophy Type 1 and Type 2

    Recruiting

    3 1 1
    Investigated drugs:
    Belgium Denmark Germany Italy Spain

  • Study on the Effects of Mexiletine for Treating Myotonic Dystrophy Types 1 and 2 in Patients

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark Germany Italy Spain

Glossary

  • Peripheral Neuropathy: A condition resulting from damage to the nerves outside of the brain and spinal cord (peripheral nerves), often causing weakness, numbness and pain, usually in the hands and feet.
  • Amitriptyline Hydrochloride: A medication typically used to treat depression, but also found to be effective in managing certain types of chronic pain, including neuropathic pain.
  • Mexiletine Hydrochloride: A medication primarily used to treat irregular heart rhythms, but also studied for its potential in managing neuropathic pain.
  • Benztropine Mesylate: A medication used in this study as an active placebo, meaning it mimics some of the side effects of the study drugs without providing the main therapeutic effect.
  • Double-Blind Study: A type of clinical trial where neither the participants nor the researchers know which treatment is being given to which participant, helping to prevent bias in the results.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect.
  • Tolerability: The degree to which side effects of a drug can be tolerated by a patient.
  • MTD (Maximum Tolerated Dose): The highest dose of a drug that does not cause unacceptable side effects.
  • Randomized: In clinical trials, this means participants are assigned by chance to different treatment groups, which helps prevent bias.

References

  1. https://clinicaltrials.gov/study/NCT00000793